LINCOLN, R.I. —MultiCell Technologies, which develops liver cell-based products for commercial and therapeutic applications, relocated its offices and laboratory into larger, more modern facilities in mid-April.
The move to the new 5,572-square-foot facility here will provide administrative and laboratory space "suitable for R&D, but also for growing the cells to meet the projected demands we expect in the not-so-distant future," says Barbara Corbett, MultiCell's investor relations manager. "The new facility is perfectly suited to liver stem cell development and growing the cells we market to companies like Pfizer and a Japanese pharmaceutical company for drug-discovery testing.
"Our licensee, XenoTech in Kansas City, indicated it did not have the space to grow to meet our anticipated need. We were talking about subcontracting to a facility near them, but decided to use our own lab space to control our own cell growth. We hope this will make a difference for speedy delivery of future orders."
The expansion will expedite developing liver cell-based products for commercial and therapeutic applications, commercial production of its immortalized hepatic cell lines and therapeutic protein products and technology.
